Caplin Point Laboratories Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-130f91b541d05c87a4a84b04.pdf

Key Takeaways


US Platform Build-Out

Sridhar Ganesan: "The important point for us is that this is no longer about only supplying products into the US. We are gradually building a much more integrated platform from R&D and manufacturing to regulatory capabilities, and also having our own label for commercial operations and direct relationships with customers."

Capacity Expansion & Demand

Sridhar Ganesan: "We are actually booked out till almost February of next year, you know. So we've been, you know, just about barely able to keep up with demand, and we know that expansion of capacity is extremely crucial for us to kind of keep up with the growing demand."

Latin America & Emerging Markets


Margins, Cash Flow & Capital Allocation

Sridhar Ganesan: "We always want to make sure that capital protection is more important than, uh, than, than the returns."

Digitization & Operational Modernization


Ameris Clinical & Backward Integration


Guidance & Commitments

CommitmentSpecificsTimeline
Gross marginRemain at similar levels around 59.8%Through FY27
Cash flow normalizationInstances causing moderation not likely to repeat same quantum; entire profit flows into PFOFrom Q2 onwards
CSL paperless80–90% digitization completed; become paperlessNext 6 months
Line 7 startCommercials begin6–7 months
Phase 3 additional lines5 more lines in new facilityBy this time next year
Product transfer to new facility9–10 months to become commercially operational in US marketFrom conversion
El Salvador supplementary tenderDecision expectedCouple of months
Ameris internal-only scopeCatering only to Caplin Point internallyNext couple of years
Regulated market factories completeAll regulated market factories with all kinds of pharmaceutical formulation2 to 2.5 years from now
Digital twinsRemote monitoring and transparency in facilitiesMaybe 1 or 2 years from now

Key Metrics

MetricQ1 FY27
Revenue growth20%, supported by 18% growth in conventional markets and 26% growth in US market
US subsidiary revenue₹43.1 crores, up from ₹14.4 crores in previous year, a threefold increase
Gross margin59.8%, in line with target; expected to remain at similar levels through the year
EBITDA margin38.4%, up from 37.1%
Operating expenses₹151 crores, up from ₹137 crores; declined as percentage of revenue from 23.7% to 23.6%
PBT₹228.2 crores, up 22.1% from ₹184.5 crores
Effective tax rate20.5%, in line with target of 20%
PAT₹1,079 crores, up 19% over previous year
Cash and cash equivalents₹1,500 crores as of June 26, up ₹266 crores
Liquid assets₹2,837 crores, up 30% or ₹668 crores from ₹2,207 crores
Shareholders' funds / net worth₹3,776 crores, up 25% or ₹762 crores from ₹3,013 crores
Warehouse stock₹505 crores, up from ₹439 crores in March, an increase of about ₹76 crores
ReceivablesUp ₹46 crores compared to March, primarily due to supplies to government
US ANDA launches39 launched out of 60-odd ANDAs held
Products in pipeline40+ products in the pipeline
Order bookBooked out till almost February of next year